{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:51:09Z","timestamp":1790257869712,"version":"4.1.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamaoncol.2018.1812","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T12:36:44Z","timestamp":1530189404000},"page":"1214","source":"Crossref","is-referenced-by-count":143,"title":["Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced\n                    <i>ERBB2\/HER2<\/i>\n                    -Positive Metastatic Breast Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Virginia F.","family":"Borges","sequence":"first","affiliation":[{"name":"University of Colorado Denver, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Ferrario","sequence":"additional","affiliation":[{"name":"Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Aucoin","sequence":"additional","affiliation":[{"name":"Cite de la Sante de Laval, Laval, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Falkson","sequence":"additional","affiliation":[{"name":"University of Alabama Comprehensive Cancer Center, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamar","family":"Khan","sequence":"additional","affiliation":[{"name":"Kansas University Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Krop","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[{"name":"London Health Science Center, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Conlin","sequence":"additional","affiliation":[{"name":"Providence Cancer Center, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Chaves","sequence":"additional","affiliation":[{"name":"Northwest Medical Specialties, Tacoma, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Cascadian Therapeutics, Inc, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Gray","sequence":"additional","affiliation":[{"name":"Cascadian Therapeutics, Inc, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Vo","sequence":"additional","affiliation":[{"name":"Cascadian Therapeutics, Inc, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Tennessee Oncology (SCRI), Nashville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi180038r3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"19","key":"coi180038r4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.","volume":"32","author":"Giordano","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4785","key":"coi180038r5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene.","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"11","key":"coi180038r6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"26","key":"coi180038r7","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"coi180038r8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"coi180038r9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer.","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"coi180038r10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"coi180038r11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/annonc\/mdp373","article-title":"An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.","volume":"21","author":"Capri","year":"2010","journal-title":"Ann Oncol"},{"issue":"12","key":"coi180038r12","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"coi180038r13","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC).","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi180038r14","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group.","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi180038r15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","article-title":"Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.","volume":"69","author":"Girish","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"coi180038r16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi180038r17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi180038r18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"30","key":"coi180038r19","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.2217\/fon-2017-0336","article-title":"Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?","volume":"13","author":"Fabi","year":"2017","journal-title":"Future Oncol"},{"issue":"34","key":"coi180038r20","doi-asserted-by":"publisher","first-page":"56921","DOI":"10.18632\/oncotarget.v8i34","article-title":"A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.","volume":"8","author":"Vici","year":"2017","journal-title":"Oncotarget"},{"issue":"29","key":"coi180038r21","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2016.67.3624","article-title":"T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.","volume":"34","author":"Dzimitrowicz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180038r22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000467387","article-title":"Systemic treatment options for HER2-positive breast cancer patients with brain metastases beyond trastuzumab: a literature review.","volume":"12","author":"Laakmann","year":"2017","journal-title":"Breast Care (Basel)"},{"issue":"4","key":"coi180038r23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","article-title":"Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.","volume":"91","author":"Clayton","year":"2004","journal-title":"Br J Cancer"},{"issue":"9897","key":"coi180038r24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"coi180038r25","first-page":"307","article-title":"Breast cancer brain metastases: new directions in systemic therapy.","volume":"7","author":"Lin","year":"2013","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"coi180038r26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi180038r27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-016-3828-6","article-title":"Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.","volume":"157","author":"Jacot","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"coi180038r28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi180038r29","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"coi180038r30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","article-title":"Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases.","volume":"34","author":"Freedman","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi180038r1","unstructured":"HowladerN, NooneAM, KrapchoM, , eds. Surveillance, Epidemiology, and End Results (SEER) cancer statistics review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015. https:\/\/seer.cancer.gov\/csr\/1975_2012\/. Accessed July 9, 2017."},{"key":"coi180038r2","unstructured":"US Cancer Statistics Working Group. United States Cancer Statistics: 1999\u20132009 Incidence and Mortality Web-based Report. Atlanta, GA: Centers for Disease Control and Prevention and National Cancer Institute, US Dept of Health and Human Services; 2013. https:\/\/www.cdc.gov\/cancer\/npcr\/pdf\/uscs_factsheet.pdf. Accessed July 9, 2017."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2686032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T12:32:20Z","timestamp":1536841940000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.1812"}},"subtitle":["A Phase 1b Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.1812","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}